ABT catalysts
Catalysts and events linked to ABT, newest first.
ABT stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli Lilly 2026-10-19 · Up | institutional defensives rebalancing | Citadel increased holding by 349% in Q2 | Not recorded |
| Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line Growth 2026-10-13 · Up | medical device sales volume acceleration driving 13.52% revenue growth | Abbott closed up 2.23% at $101.82 with Q3 revenue forecast of $12.91 billion. | Not recorded |
| Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook 2026-10-13 · Up | earnings revision momentum ahead of October 21 print | ABT gained 2.23% to $101.82 with Q3 revenue projected up 13.52% YoY. | Not recorded |
| Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings Release 2026-10-13 · Up | defensive healthcare inflows and projected double-digit top-line expansion | Source reported ABT rose 2.23% to $101.82 with Q3 revenue projected up 13.52% YoY to $12.91B and Zacks Rank #2. | Not recorded |
| Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42 2026-10-13 · Up | device volume and diagnostic sales revenue acceleration | Stock gained 2.23% to $101.82 with consensus projecting 13.52% revenue growth on Oct 21. | Not recorded |
| Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS 2026-10-13 · Up | medical device and diagnostics volume expansion flowing to quarterly revenue | Projected Q3 EPS of $1.42 (+9.23%) on $12.91B revenue (+13.52%) | Not recorded |
| Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast 2026-10-13 · Up | operating earnings and revenue expansion into Q3 results | Projected EPS of $1.42 (+9.23% YoY) and revenue of $12.91B (+13.52% YoY) scheduled for Oct 21. | Not recorded |
| Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue Forecast 2026-10-13 · Up | medtech revenue growth supporting forward operating margin expansion | Q3 earnings expected Oct 21 with consensus EPS $1.42 (+9.23% YoY) and revenue $12.91B (+13.52% YoY). | Not recorded |
Do these developments change your position?
Review ABT alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue ForecastABT
- 2026-10-13Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPSABT
- 2026-10-13Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecastABT
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecastABT
- 2026-10-13Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPSABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue ForecastABT
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-09-15Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend DemandABBV ABT
- 2026-09-15Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws CapitalABBV ABT
- 2026-09-15Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand RisesABBV ABT
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.